A multi-centre study conducted across seven antenatal clinics has reported that early gestational diabetes mellitus affects roughly one in five pregnant women. Beyond prevalence, the study suggests early GDM may represent a distinct risk profile, including a higher likelihood of developing diabetes later in life compared to GDM detected later in pregnancy—raising important questions for India’s screening strategy and maternal health policy.
What’s in the news
STRiDE study results highlight a high early-GDM burden
The study reports early GDM at 21.5% and late GDM at 19.5% among the sampled pregnant women, indicating both are rising and are of comparable magnitude.
Screening approach focused on early identification
Early screening before 16 weeks used fasting plasma glucose and HbA1c, with repeat testing at 24–28 weeks for those not identified early but at risk.
Risk-factor patterns differ between early and late GDM
Early GDM showed stronger associations with higher early-pregnancy weight, BMI, waist circumference, blood pressure, HbA1c, and family history of GDM, while late GDM linked more strongly with family history of diabetes.
Background and context
What GDM means in clinical and public health terms
Gestational diabetes is glucose intolerance first diagnosed during pregnancy. Conventionally, screening is concentrated around 24–28 weeks because pregnancy-related insulin resistance rises in mid-to-late gestation. “Early GDM” refers to hyperglycaemia detected earlier, often before 20 weeks, suggesting either earlier metabolic vulnerability or pre-existing risk unmasked by pregnancy.
Why this matters more in India
India’s reported GDM burden is significantly higher than that observed in many Western contexts. In high-burden settings, selective screening limited to only “high-risk” women can miss substantial numbers, especially where risk factors are widespread or poorly documented early in antenatal care.
Key findings from the STRiDE study
Early and late GDM are both common and rising
The headline takeaway is scale: early GDM is not a small subgroup. Its prevalence is similar to late GDM in the sample, signalling that a large share of risk may be detectable earlier than typical screening windows.
Early GDM carries a distinct metabolic-risk signature
Higher BMI, waist circumference, blood pressure and HbA1c in early pregnancy point toward a broader metabolic profile, not only a pregnancy-timed glucose spike. This supports the idea that early GDM can act as an early warning of future diabetes risk.
A predictive-risk scoring ambition
The study’s stated objective includes developing a risk scoring system to predict late GDM early in pregnancy, aiming to make screening smarter, earlier and more targeted without compromising coverage.
Why it matters
Maternal and child health outcomes hinge on timely detection
GDM is linked with complications such as large-for-gestational-age babies, birth complications, and future metabolic risks for both mother and child. Earlier identification can open a longer window for safer glucose management, nutritional counselling and monitoring.
Systems impact: antenatal care planning and load on clinics
If early screening becomes routine, health systems must plan for increased testing, follow-ups, counselling capacity, and clear referral pathways—especially in high-volume public clinics where “one more test” can translate into real operational strain.
India’s prevention opportunity extends beyond pregnancy
Pregnancy becomes a strategic entry point for long-term diabetes prevention. Early GDM detection can create a structured pathway for postpartum monitoring and lifestyle interventions, potentially reducing the future diabetes burden.
Policy and programme implications
Timing of screening needs sharper clarity
The findings strengthen the case to re-examine whether India should rely primarily on mid-pregnancy screening or incorporate earlier testing more systematically, especially where baseline risk is high.
Choice of test and practical feasibility
Different tools (fasting plasma glucose, HbA1c, oral glucose testing) vary in cost, feasibility, patient convenience and diagnostic certainty. A workable national approach needs a balance: clinically sound, operationally feasible, and equitable.
Treatment pathways must protect mother and foetus
More early diagnoses can mean more interventions. Protocols must minimise harm: avoiding overtreatment, ensuring nutrition is not compromised, and preventing unnecessary anxiety—while still preventing poor outcomes.
Arguments for and against earlier universal screening
Arguments supporting earlier screening
Early detection enables early action
Identifying risk sooner can improve monitoring and reduce complications, while also supporting long-term prevention strategies for maternal diabetes.
High-burden settings justify broader screening
Where prevalence is high, limiting screening to select “risk groups” can miss a large proportion of cases, undermining prevention.
Concerns and cautions
Risk of over-diagnosis and medicalisation
Earlier thresholds may label more women, increasing clinic load and possibly leading to unnecessary interventions if protocols are not carefully standardised.
Resource and equity constraints
Earlier and repeat testing can widen inequities if rural and under-resourced clinics cannot implement the full pathway, including counselling and follow-up.
Implementation focus areas
Standardised counselling and follow-up
A diagnosis is only useful if paired with consistent counselling, dietary guidance, and postpartum follow-up to prevent future diabetes.
Data systems for continuity of care
GDM needs a continuum approach: antenatal to postpartum. Stronger record-keeping and reminders can prevent women from being lost to follow-up after delivery.
Capacity building at primary care level
Frontline workers and primary care physicians need clear algorithms for screening, referrals, and monitoring—so early detection does not become a “paper diagnosis” without action.
Source credits
The Hindu (Chennai report based on STRiDE study findings and expert remarks)
